GoodRx (GDRX) Insider Agnes Rey-Giraud Buys 73,434 Shares
Agnes Rey-Giraud purchased 73,434 shares of GoodRx Holdings, Inc. on June 16, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Agnes Rey-Giraud bought 73,434 shares of GoodRx Holdings, Inc. ($GDRX) on June 16, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $GDRX is down 2.2% after 1 week, up 14.3% after 1 month and up 23.1% to date (from the $2.73 close on Jun 16, 2026).
GDRX
GoodRx Holdings, Inc.
Key Points
- Agnes Rey-Giraud purchased 73,434 shares of GoodRx Holdings, Inc. on June 16, 2026.
- GoodRx shares are trading at $2.73 with a market cap of $924.6 million and a P/E ratio of 45.5.
- Institutional investors like LSV Asset Management and Ameriprise Financial Inc. have also adjusted their positions in GoodRx.
Get $GDRX trade alerts by text
We text you when insiders, Congress or big funds trade $GDRX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated GoodRx Holdings, Inc. alert may contain errors. Disclosures
On June 16, 2026, Agnes Rey-Giraud acquired 73,434 shares of GoodRx Holdings, Inc. (NasdaqGS: GDRX). This insider purchase comes as GoodRx shares are trading at $2.73.
Other Institutional Activity in GoodRx Holdings, Inc.
Several institutional investors have recently adjusted their holdings in GoodRx. LSV Asset Management increased its stake by 2,156,031 shares, bringing its total to 4,981,931 shares valued at about $9.77 million. Ameriprise Financial Inc. also boosted its position by 1,183,329 shares, ending with 4,455,760 shares worth approximately $8.73 million. Vanguard Capital Management LLC and Vanguard Portfolio Management LLC both initiated new positions, each holding 4,261,516 and 3,362,864 shares, respectively, valued at $8.35 million and $6.59 million. Meanwhile, Francisco Partners Management, LP and Silver Lake Group, L.L.C. maintained their existing positions.
GoodRx Holdings, Inc. Stock Down 22.8%
Shares of GoodRx Holdings, Inc. are trading near $2.73 on the NasdaqGS. The company has a market capitalization of approximately $924.6 million and a P/E ratio of 45.5, with a forward P/E of 7.62. GoodRx's stock has a 52-week range between $1.77 and $5.81. The stock's 50-day moving average is $2.54, while the 200-day moving average is $2.89. The company has a beta of 1.615, indicating moderate volatility compared to the market.
Recent Earnings
GoodRx Holdings reported revenue of $787.9 million, although it experienced a slight decline in revenue growth at -4.4%. The company's earnings per share (EPS) stand at $0.06, with a net margin of 2.6% and a return on equity (ROE) of 3.2%. GoodRx is expected to announce its next earnings on August 5, 2026.
Insider Buying and Selling at GoodRx Holdings, Inc.
On June 16, 2026, several insiders, including Douglas Joseph Hirsch, Kelly Kennedy, Ronald Bruehlman, Scott Wagner, and Trevor Bezdek, purchased 73,434 shares each of GoodRx Holdings, Inc. These transactions were not part of a pre-planned trading program.
Analysts Set New Price Targets
Analysts have been active in setting price targets for GoodRx. On May 14, 2026, Citigroup maintained a 'buy' rating with a price target of $4.00. TD Cowen also maintained a 'buy' rating with the same target on May 11, 2026. Wells Fargo set a $3.50 target on March 4, 2026, with a 'buy' rating. The consensus among analysts is a 'hold' rating, with an average price target of $3.18 based on 13 opinions.
About GoodRx Holdings, Inc.
GoodRx Holdings, Inc. is a healthcare company based in Santa Monica, California. It provides a platform for consumers to compare prescription drug prices and access negotiated savings. The company offers various healthcare products and services, including subscription programs and telehealth services through GoodRx Care. GoodRx also caters to the needs of pet owners with products for dogs, cats, and other animals. Founded in 2011, the company is led by CEO Wendy Barnes and employs around 697 people.
Bottom Line
Agnes Rey-Giraud's purchase of GoodRx shares highlights ongoing interest in the company. While the stock is currently trading at $2.73, it remains under close watch by both institutional investors and analysts. Insider purchases and consistent analyst ratings suggest a continued focus on GoodRx's performance in the healthcare sector.
Related Filing Alerts
Source: Agnes Rey-Giraud's Form 4 filing on $GDRX (Jun 16, 2026). Find the original filing: GDRX Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts